Genetic Modeling of B-cell State Transitions for Rational Design of Lymphoma Therapies-Reference-Cited by-同舟云学术

Genetic Modeling of B-cell State Transitions for Rational Design of Lymphoma Therapies

Published:2022-12-19 Issue:1 Volume:4 Page:8-11
ISSN:2643-3230
Container-title:Blood Cancer Discovery
language:en
Short-container-title:

Author:

Leveille Etienne¹²^ORCID,Kothari Shalin¹²^ORCID,Müschen Markus¹²³^ORCID

Affiliation:

1. 1Center of Molecular and Cellular Oncology, Yale University, New Haven, Connecticut.

2. 2Department of Internal Medicine, Yale University, New Haven, Connecticut.

3. 3Department of Immunobiology, Yale University, New Haven, Connecticut.

Abstract

Summary:The use of genomic data to analyze primary endpoints for clinical trials in diffuse large B-cell lymphomas (DLBCL) significantly improved the development of rational drug combinations for genetically defined patient subsets. Recent genetic mouse models and their ability to recapitulate transitions between germinal center exit and memory B-cell characteristics in DLBCL will accelerate the development of rationale-based clinical trials.See related article by Flümann et al., p. 78 (3).See related article by Venturutti et al., (5).

Publisher

American Association for Cancer Research (AACR)

Subject

General Medicine

Link

https://aacrjournals.org/bloodcancerdiscov/article-pdf/doi/10.1158/2643-3230.BCD-22-0180/3232340/bcd-22-0180.pdf

Reference10 articles.

1. A probabilistic classification tool for genetic subtypes of diffuse large B cell lymphoma with therapeutic implications;Wright;Cancer Cell,2020

2. Effect of ibrutinib with R-CHOP chemotherapy in genetic subtypes of DLBCL;Wilson;Cancer Cell,2021

3. Distinct genetically determined origins of /-driven aggressive lymphoma rationalize targeted therapeutic intervention strategies;Flümann;Blood Cancer Discov,2023

4. Aberrant expansion of spontaneous splenic germinal centers induced by hallmark genetic lesions of aggressive lymphoma;Pindzola;Blood,2022

5. An aged/autoimmune B-cell program defines the early transformation of extranodal lymphomas;Venturutti;Cancer Discov,2022 20 [ ]